SG11202110449YA - Small molecule degraders of stat3 - Google Patents
Small molecule degraders of stat3Info
- Publication number
- SG11202110449YA SG11202110449YA SG11202110449YA SG11202110449YA SG11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA SG 11202110449Y A SG11202110449Y A SG 11202110449YA
- Authority
- SG
- Singapore
- Prior art keywords
- stat3
- small molecule
- molecule degraders
- degraders
- small
- Prior art date
Links
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 title 1
- 239000001064 degrader Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823949P | 2019-03-26 | 2019-03-26 | |
| US201962884995P | 2019-08-09 | 2019-08-09 | |
| PCT/US2020/024892 WO2020198435A1 (en) | 2019-03-26 | 2020-03-26 | Small molecule degraders of stat3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110449YA true SG11202110449YA (en) | 2021-10-28 |
Family
ID=70286026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110449YA SG11202110449YA (en) | 2019-03-26 | 2020-03-26 | Small molecule degraders of stat3 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230083015A1 (en) |
| EP (1) | EP3946619A1 (en) |
| JP (1) | JP2022527298A (en) |
| KR (1) | KR20220009941A (en) |
| CN (1) | CN114269763A (en) |
| AU (1) | AU2020248002A1 (en) |
| CA (1) | CA3134822A1 (en) |
| IL (1) | IL286567A (en) |
| MA (1) | MA55516A (en) |
| MX (1) | MX2021011753A (en) |
| SG (1) | SG11202110449YA (en) |
| WO (1) | WO2020198435A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4112614A4 (en) | 2020-02-25 | 2023-09-06 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| MX2022011437A (en) * | 2020-03-17 | 2022-10-03 | Kymera Therapeutics Inc | Stat degraders and uses thereof. |
| IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| WO2023133336A1 (en) * | 2022-01-10 | 2023-07-13 | Recludix Pharma, Inc. | Stat modulators and uses thereof |
| CN117126231A (en) * | 2022-05-25 | 2023-11-28 | 杭州和正医药有限公司 | Peptoid STAT protein degradation agent, composition and application thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| JP2001523958A (en) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | CTLA-4 binding peptides for immunotherapy |
| JP4896327B2 (en) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | PD-1, B7-4 receptors and uses thereof |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ATE481985T1 (en) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | IMMUNOPOTENTATING COMPOSITIONS |
| SI2439273T1 (en) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101586617B1 (en) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | Antibodies to human programmed death receptor PD-1 |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| PE20110435A1 (en) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | ANTAGONIST COMPOSITIONS OF PD-1 |
| WO2010077589A2 (en) | 2008-12-08 | 2010-07-08 | The Regents Of The University Of Michigan Office Of Technology Transfer | Stat3 inhibitors and therapeutic methods using the same |
| UA109108C2 (en) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Anti-pd-ll antibody and its use to enhance t-cell function |
| JP4965623B2 (en) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Method, system, and program for supporting input of execution parameters of predetermined software to input field |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| DK2785375T3 (en) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
| JP6448533B2 (en) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling |
| AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| US10513540B2 (en) | 2012-07-31 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| JP6224739B2 (en) | 2013-03-15 | 2017-11-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Anti-LAG-3 binding protein |
| KR20240056664A (en) | 2013-09-11 | 2024-04-30 | 메디뮨 리미티드 | Anti-b7-h1 antibodies for treating tumors |
| US9828399B2 (en) * | 2014-02-28 | 2017-11-28 | The Royal Institution For The Advancement Of Learning/Mcgill University | TC-PTP inhibitors as APC activators for immunotherapy |
| CU24481B1 (en) | 2014-03-14 | 2020-03-04 | Immutep Sas | ANTIBODY MOLECULES THAT JOIN LAG-3 |
| CA3073755A1 (en) * | 2017-08-24 | 2019-02-28 | The Royal Institution For The Advancement Of Learning/Mcgill Universit | Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp) |
-
2020
- 2020-03-26 AU AU2020248002A patent/AU2020248002A1/en not_active Abandoned
- 2020-03-26 CA CA3134822A patent/CA3134822A1/en active Pending
- 2020-03-26 EP EP20719095.0A patent/EP3946619A1/en not_active Withdrawn
- 2020-03-26 WO PCT/US2020/024892 patent/WO2020198435A1/en unknown
- 2020-03-26 US US17/442,666 patent/US20230083015A1/en active Pending
- 2020-03-26 JP JP2021557614A patent/JP2022527298A/en active Pending
- 2020-03-26 MX MX2021011753A patent/MX2021011753A/en unknown
- 2020-03-26 KR KR1020217034009A patent/KR20220009941A/en unknown
- 2020-03-26 MA MA055516A patent/MA55516A/en unknown
- 2020-03-26 CN CN202080039100.9A patent/CN114269763A/en active Pending
- 2020-03-26 SG SG11202110449YA patent/SG11202110449YA/en unknown
-
2021
- 2021-09-22 IL IL286567A patent/IL286567A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021011753A (en) | 2022-01-31 |
| EP3946619A1 (en) | 2022-02-09 |
| JP2022527298A (en) | 2022-06-01 |
| US20230083015A1 (en) | 2023-03-16 |
| AU2020248002A1 (en) | 2021-10-21 |
| KR20220009941A (en) | 2022-01-25 |
| MA55516A (en) | 2022-02-09 |
| WO2020198435A1 (en) | 2020-10-01 |
| CA3134822A1 (en) | 2020-10-01 |
| CN114269763A (en) | 2022-04-01 |
| IL286567A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286567A (en) | Small molecule degraders of stat3 | |
| EP3787747A4 (en) | Small molecule degraders of polybromo-1 (pbrm1) | |
| IL275761A (en) | Benzamide compounds | |
| GB2570922B (en) | Purification of hydrocarbons | |
| SG11202010347XA (en) | Stat3 inhibitors | |
| EP3766529A4 (en) | Composition for purification of biofluids | |
| EP3723757A4 (en) | Small molecule degraders that recruit dcaft15 | |
| IL271790B1 (en) | Chromatography process for purification of biomolecules | |
| GB2587720B (en) | Structural analysis of ionised molecules | |
| IL287876A (en) | Jak inhibitors | |
| EP3857635A4 (en) | Chemical prealkaliation of electrodes | |
| IL252533A0 (en) | Planar transformer components comprising electrophoretically deposited coating | |
| EP3320901A4 (en) | Application of dimethylamino micheliolide | |
| SG11202104554QA (en) | Coating solution | |
| IL267782B (en) | Chemical entities suitable for therapy | |
| IL290381A (en) | Jak inhibitors | |
| IL289266A (en) | Novel molecules | |
| GB2603344B (en) | Cachability of single page applications | |
| ZA202105399B (en) | Use of spiropidion | |
| SG11202105136WA (en) | Application of chidamide | |
| IL291611A (en) | Jak inhibitors | |
| GB201919193D0 (en) | Novel molecules | |
| GB201912688D0 (en) | Novel Molecules | |
| GB2584687B (en) | Crystallisation of chemical molecules | |
| GB201809911D0 (en) | Use of trpv1 agonists |